Choosing a preclinical contract research organization: matching the disease models and the xenograft work to the question, deciding which preclinical services genuinely need GLP, and the contract research organization services terms that decide who owns the data
Preclinical work is outsourced for capacity and for models, and the commonest expensive mistake is choosing on price for a study whose result will be used to make a go or no-go decision. The model, the conduct standard and the contract each decide whether the data survives scrutiny. This page covers the three in the order they should be settled.
- good laboratory practice, the standard a pivotal safety study runs under
- Part 58
- the NIH policy the animal work is conducted under
- PHS Policy
- the electronic records rule governing the study data system
- Part 11
Figures in this panel are the conduct, welfare and records instruments a preclinical study is run under, named from the regulations and policies themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a service price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Selecting and scoping the work
- Start from the question, and let it choose the model. Efficacy, mechanism and safety ask different things. Disease models vary enormously in how well they predict, and a provider's familiarity with one model is worth more than a slightly lower price on another. Ask what they run weekly, not what they can run.
- Specify xenograft work properly or expect to repeat it. A xenograft study's result depends on the cell line and its authentication, the host strain and its immune status, the implantation site, the randomisation point by tumour volume and the endpoint definition. Any of these left to the provider's default is a variable you cannot reconstruct later.
- Decide the conduct standard deliberately. Pivotal safety studies supporting a regulatory submission are conducted under good laboratory practice. Exploratory efficacy work generally is not, and conducting it to that standard adds cost without adding value. Deciding this late means repeating studies.
- Read the animal welfare and quality position before the quotation. Institutional approval, facility accreditation, veterinary oversight and the humane endpoints in the protocol are documents, not assurances. They will be asked for later by a reviewer or a regulator.
- Settle data, samples and intellectual property in the contract. Who owns the raw data, who holds the residual samples and for how long, what happens to a derived model or cell line, and who may publish. These are negotiable at contract and effectively fixed afterwards.
Study design questions worth settling before the quotation
Group sizes justified by a power calculation, randomisation and blinding where the endpoint is subjective, and a pre-specified analysis. These cost nothing to specify and are what makes the difference between a result and an anecdote.
Agree what happens to animals removed from study and how those are handled in the analysis. Exclusions decided after the fact are the single most common reason a striking preclinical result does not replicate.
Managing the study once it is running
Ask for interim data at agreed points rather than a report at the end. A study drifting off protocol is recoverable in week two and not in week ten, and providers generally welcome the contact.
Name one person on each side with authority to make a protocol decision. Studies delayed by a question nobody was empowered to answer are a recurring and entirely avoidable cost.
Reading the report
The report should carry the protocol and its amendments, the raw data or a clear route to it, all deviations with their assessment, and the analysis as pre-specified. A report presenting only the favourable analysis is not a report you can build a programme on.
Request the data in analysable form. Reconstructing a dataset from tables in a document introduces errors and makes independent re-analysis effectively impossible.
Common questions
- How do I choose a preclinical contract research organization?
- On model experience first, quality systems second, price third. A provider running your model routinely will produce cleaner data and spot a problem sooner than one running it for the first time at a lower rate.
- Does every preclinical study need GLP?
- No. Good laboratory practice applies to the safety studies supporting a submission. Exploratory efficacy and mechanism work is usually not conducted under it, and conducting it there adds cost without improving the science.
- What should a xenograft study protocol fix in advance?
- Cell line identity and authentication, host strain, implantation site and cell number, the tumour volume at which animals are randomised, the measurement schedule, the humane endpoint and the statistical plan. Each one changes the result.
- Who owns the data from contract research organization services?
- Whatever the contract says. Assume nothing: raw data ownership, residual sample custody, the right to publish and the ownership of anything derived are separate clauses and defaults differ between providers.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/preclinical-cro/.